EBS analyst estimates
Emergent BioSolutions (EBS) analyst ratings, the average price target and its range, and every firm's latest call.
EBS analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 10, 2026 | H.C. Wainwright | Emergent BioSolutions price target lowered to $10 from $12 at H.C. Wainwright | $10.00 |
| Mar 9, 2026 | H.C. Wainwright | Emergent BioSolutions price target lowered to $12 from $15 at H.C. Wainwright | $12.00 |
| May 4, 2022 | Wells Fargo | Wells Fargo Maintains Equal-Weight on Emergent BioSolutions, Lowers Price Target to $38 | $38.00 |
| Apr 29, 2022 | Chardan Capital | Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $65 | $65.00 |
- 2 firms rate EBS: 1 buy, 0 hold, 1 sell.
- The average price target is $10.00 from 1 analysts, from $10.00 to $10.00.
Updated 2026-11-03 23:13 UTC